The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | DESTINY-PanTumor02: trastuzumab deruxtecan in BTC and pancreatic cancer
Do-Youn Oh, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, gives an overview of the DESTINY-PanTumor02 study (NCT04482309), which explores the safety and efficacy of trastuzumab deruxtecan in HER2-expressing biliary tract cancer (BTC) and pancreatic cancer. Significant clinical benefit was demonstrated in the BTC cohort, whereas in the pancreatic cancer cohort, response rates were lower, but the data still suggest potential efficacy. Safety outcomes were consistent with known profiles, with manageable adverse events. These findings support further investigation of T-DXd as a treatment option for HER2-expressing BTC and pancreatic cancer. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
